Literature DB >> 16775089

Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI).

J Ge1, Y Li, J Qian, J Shi, Q Wang, Y Niu, B Fan, X Liu, S Zhang, A Sun, Y Zou.   

Abstract

OBJECTIVE: To study whether emergent intracoronary autologous bone marrow cell transplantation (BMT) is applicable for the treatment of acute myocardial infarction (AMI).
METHODS: 20 patients admitted within 24 h after the onset of a first AMI were randomly allocated to receive intracoronary autologous BMT (n = 10) or bone marrow supernatant (controls, n = 10) immediately after primary percutaneous coronary intervention. Left ventricular ejection fraction (LVEF), left ventricular end diastolic internal diameter (LVDd) and myocardial perfusion defect scores were examined respectively by echocardiography and single-photon emission computed tomography at one week and six months after AMI.
RESULTS: From one week to six months after AMI, LVEF was enhanced from mean 53.8 (SD 9.2)% to 58.6 (9.9)% (p < 0.05) in the BMT group but was unchanged in the control group (58.2 (7.5)% v 56.3 (3.5)%, p > 0.05); LVDd remained unchanged (52.5 (2.8) v 52.1 (3.2) mm, p > 0.05) in the BMT group but was significantly enlarged in the control group (50.4 (6.0) v 55.2 (7.1) mm, p < 0.05). Additionally, myocardial perfusion defect scores decreased from 21 (11) to 13 (10) (p < 0.01) in the BMT group but were unchanged in the control group (20 (14) v 17 (15), p > 0.05).
CONCLUSION: Emergent intracoronary transplantation of bone marrow mononuclear cells after AMI is practicable, and it improved cardiac function, prevented myocardial remodelling and increased myocardial perfusion at six months' follow up.

Entities:  

Mesh:

Year:  2006        PMID: 16775089      PMCID: PMC1861266          DOI: 10.1136/hrt.2005.085431

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.

Authors:  Stefan Janssens; Christophe Dubois; Jan Bogaert; Koen Theunissen; Christophe Deroose; Walter Desmet; Maria Kalantzi; Lieven Herbots; Peter Sinnaeve; Joseph Dens; Johan Maertens; Frank Rademakers; Steven Dymarkowski; Olivier Gheysens; Johan Van Cleemput; Guy Bormans; Johan Nuyts; Ann Belmans; Luc Mortelmans; Marc Boogaerts; Frans Van de Werf
Journal:  Lancet       Date:  2006-01-14       Impact factor: 79.321

2.  The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats.

Authors:  G Heba; T Krzemiński; M Porc; J Grzyb; A Ratajska; A Dembińska-Kieć
Journal:  J Vasc Res       Date:  2001 May-Jun       Impact factor: 1.934

3.  Quantitative assessment of motion artifacts and validation of a new motion-correction program for myocardial perfusion SPECT.

Authors:  N Matsumoto; D S Berman; P B Kavanagh; J Gerlach; S W Hayes; H C Lewin; J D Friedman; G Germano
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

4.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

5.  Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.

Authors:  A A Kocher; M D Schuster; M J Szabolcs; S Takuma; D Burkhoff; J Wang; S Homma; N M Edwards; S Itescu
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

6.  Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium.

Authors:  Yao Liang Tang; Qiang Zhao; Y Clare Zhang; Leilei Cheng; Mingya Liu; Jianhui Shi; Yin Zeng Yang; Chuizhen Pan; Junbo Ge; M Ian Phillips
Journal:  Regul Pept       Date:  2004-01-15

7.  Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.

Authors:  M B Britten; N D Abolmaali; B Assmus; R Lehmann; J Honold; J Schmitt; T J Vogl; H Martin; V Schächinger; S Dimmeler; A M Zeiher
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

8.  Enhanced cytoprotection and angiogenesis by bone marrow cell transplantation may contribute to improved ischemic myocardial function.

Authors:  Shaoheng Zhang; Ping Zhang; Jingxuan Guo; Zhuqing Jia; Kangtao Ma; Yonggang Liu; Chunyan Zhou; Linsong Li
Journal:  Eur J Cardiothorac Surg       Date:  2004-02       Impact factor: 4.191

9.  Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction.

Authors:  Shao-liang Chen; Wu-wang Fang; Fei Ye; Yu-Hao Liu; Jun Qian; Shou-jie Shan; Jun-jie Zhang; Robert Zhao Chunhua; Lian-ming Liao; Song Lin; Jing-ping Sun
Journal:  Am J Cardiol       Date:  2004-07-01       Impact factor: 2.778

10.  Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation.

Authors:  Shinji Tomita; Donald A G Mickle; Richard D Weisel; Zhi-Qiang Jia; Laura C Tumiati; Yasmin Allidina; Peter Liu; Ren-Ke Li
Journal:  J Thorac Cardiovasc Surg       Date:  2002-06       Impact factor: 5.209

View more
  44 in total

Review 1.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

2.  Stem cells to repair the broken heart: much ado about nothing?

Authors:  M Saha; R Zbinden; S R Redwood; M S Marber
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

3.  Cell therapy for myocardial infarction.

Authors:  Yoo-Wook Kwon; Han-Mo Yang; Hyun-Jai Cho
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 4.  Pregenerative medicine: developmental paradigms in the biology of cardiovascular regeneration.

Authors:  B Alexander Yi; Oliver Wernet; Kenneth R Chien
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

5.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 6.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

Review 7.  Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Authors:  Paulino A Alvarez; Ernst R Schwarz; Rajesh Ramineni; Phil Myatt; Clay Barbin; Carlos Boissonnet; Anita Phan; Aldo Maggioni; Alejandro Barbagelata
Journal:  Clin Res Cardiol       Date:  2012-09-28       Impact factor: 5.460

Review 8.  Cardiac repair with adult bone marrow-derived cells: the clinical evidence.

Authors:  Buddhadeb Dawn; Ahmed Abdel-Latif; Santosh K Sanganalmath; Michael P Flaherty; Ewa K Zuba-Surma
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

9.  Endothelial progenitor cells: what use for the cardiologist?

Authors:  Aurangzeb Siddique; Eduard Shantsila; Gregory Yh Lip; Chetan Varma
Journal:  J Angiogenes Res       Date:  2010-02-22

10.  Phases I-III Clinical Trials Using Adult Stem Cells.

Authors:  Ricardo Sanz-Ruiz; Enrique Gutiérrez Ibañes; Adolfo Villa Arranz; María Eugenia Fernández Santos; Pedro L Sánchez Fernández; Francisco Fernández-Avilés
Journal:  Stem Cells Int       Date:  2010-11-04       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.